- Home
- OPRA vs COAG Comparison
OPRA vs COAG Comparison
Compare OPRA & COAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OPRA | COAG |
|---|---|---|
| Founded | 1996 | N/A |
| Country | Norway | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.9B |
| IPO Year | 2018 | 2026 |
Fundamental Metrics
Financial Performance| Metric | OPRA | COAG |
|---|---|---|
| Price | $17.67 | $36.80 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $21.50 | N/A |
| AVG Volume (30 Days) | 308.7K | ★ 377.8K |
| Earning Date | 04-28-2026 | N/A |
| Dividend Yield | ★ 4.61% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $21.29 | N/A |
| Revenue Next Year | $15.34 | N/A |
| P/E Ratio | $13.62 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.71 | $27.47 |
| 52 Week High | $21.06 | $55.42 |
Technical Indicators
Market Signals| Indicator | OPRA | COAG |
|---|---|---|
| Relative Strength Index (RSI) | 40.83 | N/A |
| Support Level | $17.79 | N/A |
| Resistance Level | $19.43 | N/A |
| Average True Range (ATR) | 0.50 | 0.00 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 40.56 | 0.00 |
Price Performance
Historical ComparisonAbout OPRA Opera Limited
Opera Ltd is a consumer internet software company providing a diversified portfolio of high-performance web browsers and adjacent digital services to engaged user base The company has transitioned from browser developer to multi-faceted platform offering a products and services that include PC and mobile browsers, its Opera Gaming portals and development tools, Opera News content platforms, Opera Ads platform, as well as a number of AI and web3 products and services, such as MiniPay and Opera AI, to a user base.
About COAG Hemab Therapeutics Holdings Inc. Common Stock
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.